Brief: Shanghai Junshi Biosciences Says Regular Approval Of Toripalimab As Second-Line Or Later Treatment Of Melanoma By NMPA
06/01/2025 13:20
Jan 6 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* REGULAR APPROVAL OF TORIPALIMAB AS SECOND-LINE OR LATER
TREATMENT OF MELANOMA BY NMPA
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab